Evidence map›Paper›PMID 40529069›Full record

ArticleACS medicinal chemistry letters2025

Benzosuberene and Tetracyclic Analogues as Colchicine Site Inhibitors of Tubulin Polymerization.

Jennifer M VanNatta, Graham J Carlson, Haichan Niu, Ruoli Bai, Hashini I Wanniarachchi, Regan Schuetze, Mary Lynn Trawick, Ernest Hamel, Ralph P Mason, Kevin G Pinney

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jennifer M VanNattaDepartment of Chemistry and Biochemistry, Baylor University, One Bear Place, No. 97348, Waco, Texas 76798-7348, United States.
Graham J CarlsonDepartment of Chemistry and Biochemistry, Baylor University, One Bear Place, No. 97348, Waco, Texas 76798-7348, United States.
Haichan NiuDepartment of Chemistry and Biochemistry, Baylor University, One Bear Place, No. 97348, Waco, Texas 76798-7348, United States.
Ruoli BaiMolecular Pharmacology Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702, United States.
Hashini I WanniarachchiDepartment of Radiology, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390-9058, United States.
Regan SchuetzeDepartment of Radiology, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390-9058, United States.
Mary Lynn TrawickDepartment of Chemistry and Biochemistry, Baylor University, One Bear Place, No. 97348, Waco, Texas 76798-7348, United States.
Ernest HamelMolecular Pharmacology Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702, United States.
Ralph P MasonDepartment of Radiology, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390-9058, United States.ORCID https://orcid.org/0000-0001-7517-3721
Kevin G PinneyDepartment of Chemistry and Biochemistry, Baylor University, One Bear Place, No. 97348, Waco, Texas 76798-7348, United States.ORCID https://orcid.org/0000-0003-1262-8631

Funding

UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Kathryn Ann O'Donnell · 2010 to 2026
$53.7M
Vascular image-guided optimization of response (VIGOR) to therapy in kidney cancerR01CA244579 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI LIU, LI, PINNEY, KEVIN G. · 2020 to 2024
$2.4M
Novel Protein Engineered Drug Conjugates Targeting Phosphatidylserine for the Treatment of Breast CancerR01CA238624 · NCI · BAYLOR UNIVERSITY · PI BREKKEN, ROLF A, PINNEY, KEVIN G. · 2020 to 2023
$1.9M
Chemotherapeutic Agents with Enhanced Selectivity for the Tumor MicroenvironmentR01CA140674 · NCI · BAYLOR UNIVERSITY · PI PINNEY, KEVIN G., TRAWICK, MARY LYNN · 2010 to 2014
$1.4M
NCI NIH HHS P30 CA142543NCI NIH HHS R01 CA140674NCI NIH HHS R01 CA238624NCI NIH HHS R01 CA244579
6 · The paper itself

Abstract

Colchicine site inhibitors of tubulin polymerization function as antiproliferative anticancer agents, with certain inhibitors demonstrating a dual mechanism of action as tumor-selective vascular disrupting agents (VDAs). Our previous studies yielded potent benzosuberene-based colchicine site inhibitors of tubulin polymerization. To expand structure-activity correlations, the seven-membered fused ring and the pendant ring were modified to generate a series of new compounds, 11 being strong inhibitors (IC

Indexed as

antiproliferative agentsbenzosuberene-based moleculesinhibitors of tubulin polymerizationvascular disrupting agents (VDAs)

Identifiers

PMID40529069
PMCPMC12169467

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.